Skip to main content

Table 2 Stage-specific estimates of prevalence of patients requiring active anti-tumour therapy for colorectal cancer in the Czech Republic in 2015 according to the eight scenarios

From: Estimating the number of colorectal cancer patients treated with anti-tumour therapy in 2015: the analysis of the Czech National Cancer Registry

  Scenario 1: Constant proportion of treated patients;
Constant incidence rate; Constant survival rates
Scenario 2: Constant proportion of treated patients;
Constant incidence rate; Improving survival rates
Stage at diagnosis Newly diagnosed patients Non-terminal cancer recurrence Terminal
cancer recurrence
Total Newly diagnosed patients Non-terminal cancer recurrence Terminal
cancer recurrence
Total
Stage I+II 3,650 565 479 4,694 3,650 607 524 4,781
Stage III 1,783 355 541 2,679 1,783 407 625 2,815
Stage IV 1,419 181 766 2,366 1,419 212 898 2,529
Missing 220 16 99 335 220 13 76 309
All cases 7,072 1,117 1,885 10,074 7,072 1,239 2,123 10,434
  Scenario 3: Constant proportion of treated patients;
Modelled incidence rate; Constant survival rates
Scenario 4: Constant proportion of treated patients;
Modelled incidence rate; Improving survival rates
Stage at diagnosis Newly diagnosed patients Non-terminal cancer recurrence Terminal
cancer recurrence
Total Newly diagnosed patients Non-terminal cancer recurrence Terminal
cancer recurrence
Total
Stage I+II 3,581 547 467 4,595 3,581 589 511 4,681
Stage III 2,223 422 632 3,277 2,223 475 725 3,423
Stage IV 1,428 177 761 2,366 1,428 207 892 2,527
Missing 131 10 59 200 131 9 47 187
All cases 7,363 1,156 1,919 10,438 7,363 1,280 2,175 10,818
  Scenario 5: Modelled proportion of treated patients;
Constant incidence rate; Constant survival rates
Scenario 6: Modelled proportion of treated patients;
Constant incidence rate; Improving survival rates
Stage at diagnosis Newly diagnosed patients Non-terminal cancer recurrence Terminal
cancer recurrence
Total Newly diagnosed patients Non-terminal cancer recurrence Terminal
cancer recurrence
Total
Stage I+II 3,613 560 562 4,735 3,613 602 613 4,828
Stage III 1,831 362 628 2,821 1,831 415 727 2,973
Stage IV 1,675 206 890 2,771 1,675 241 1,038 2,954
Missing 122 9 121 252 122 7 92 221
All cases 7,241 1,137 2,201 10,579 7,241 1,265 2,470 10,976
  Scenario 7: Modelled proportion of treated patients;
Modelled incidence rate; Constant survival rates
Scenario 8: Modelled proportion of treated patients;
Modelled incidence rate; Improving survival rates
Stage at diagnosis Newly diagnosed patients Non-terminal cancer recurrence Terminal
cancer recurrence
Total Newly diagnosed patients Non-terminal cancer recurrence Terminal
cancer recurrence
Total
Stage I+II 3,542 544 549 4,635 3,542 583 599 4,724
Stage III 2,285 429 734 3,448 2,285 484 844 3,613
Stage IV 1,697 203 887 2,787 1,697 236 1,036 2,969
Missing 72 5 71 148 72 5 57 134
All cases 7,596 1,181 2,241 11,018 7,596 1,308 2,536 11,440